Maintenance of improved lipid levels following attendance at a cardiovascular risk reduction clinic: a 10-year experience

Background: Specialty cardiovascular risk reduction clinics (CRRC) increase the proportion of patients attaining recommended lipid targets; however, it is not known if the benefits are sustained after discharge. We evaluated the impact of a CRRC on lipid levels and assessed the long-term effect of a CRRC in maintaining improved lipid levels following discharge. Methods: The medical records of consecutive dyslipidemic patients discharged ×6 months from a tertiary hospital CRRC from January 1991 to January 2001 were retrospectively reviewed. The primary outcome was the change in patients’ lipid levels between the final CRRC visit and the most recent primary care follow-up. A worst-case analysis was conducted to evaluate the potential impact of the patients in whom the follow-up lipid profiles post-discharge from the CRRC were not obtained. Results: Within the CRRC (median follow-up = 1.28 years in 1064 patients), we observed statistically significant improvements in all lipid parameters. In the 411 patients for whom post-discharge lipid profiles were available (median follow-up = 2.41 years), there were no significant differences observed in low-density lipoprotein-cholesterol, total cholesterol (TC), or triglycerides since CRRC discharge; however, there were small improvements in high-density lipoprotein-cholesterol (HDL-C) and TC:HDL ratio (p < 0.05 for both). The unadjusted worst-case analysis (653 patients with no follow-up lipid profiles) demonstrated statistically significant worsening of all lipid parameters between CRRC discharge and the most recent follow-up. However, when the change in lipid parameters between the baseline and the most recent follow-up was assessed in this analysis, the changes in all lipid parameters were significantly improved (p < 0.05). Conclusions: This study demonstrates that a CRRC can improve lipid levels and suggests that these benefits are sustained once patients are returned to the care of their primary physician.

[1]  Allison L Egger,et al.  Results of Retrospective Chart Review to Determine Improvement in Lipid Goal Attainment in Patients Treated by High-Volume Prescribers of Lipid-Modifying Drugs , 2006, Journal of managed care pharmacy : JMCP.

[2]  R. McPherson,et al.  Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. , 2006, The Canadian journal of cardiology.

[3]  C. Cooke,et al.  Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland-based health maintenance organization. , 2006, Clinical therapeutics.

[4]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[5]  J. Merenich,et al.  Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization. , 2005, Archives of internal medicine.

[6]  D. Hunninghake,et al.  Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. , 2004, Journal of the American College of Cardiology.

[7]  R. Zimlichman,,et al.  Follow-up in a lipid clinic improves the management of risk factors in cardiovascular disease patients. , 2002, The Israel Medical Association journal : IMAJ.

[8]  G. Francis,et al.  Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. , 2002, The American journal of cardiology.

[9]  J. Pippins,et al.  Does a Lipid Clinic Increase Compliance With National Cholesterol Education Program Treatment Guidelines?: Report of a Case-Matched Controlled Study , 2001, Southern medical journal.

[10]  J. Frohlich,et al.  Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[11]  T. Pearson,et al.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. , 2000, Archives of internal medicine.

[12]  J. Gurwitz,et al.  Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease , 1999, Journal of General Internal Medicine.

[13]  S M Grundy,et al.  Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 1999, Circulation.

[14]  R. Herman,et al.  A cardiovascular risk factor reduction clinic. , 1999, The Canadian journal of cardiology.

[15]  T. Pearson,et al.  Lipid lowering in a multidisciplinary clinic compared with primary physician management. , 1998, The American journal of cardiology.

[16]  Alan D. Lopez,et al.  Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study , 1997, The Lancet.

[17]  Bittner,et al.  Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group. , 1997, JAMA.

[18]  David M. Herrington,et al.  Adherence to National Cholesterol Education Program Treatment Goals in Postmenopausal Women With Heart Disease: The Heart and Estrogen/Progestin Replacement Study (HERS) , 1997 .

[19]  R. Krauss,et al.  A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. , 1996, JAMA.

[20]  L. Wexler,et al.  Reducing low-density lipoprotein cholesterol levels in an ambulatory care system. Results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based care. , 1995 .

[21]  D. Jacobs,et al.  Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial , 1992 .

[22]  J. Hainer.  Cholesterol and mortality. , 1987, JAMA.

[23]  D. Levy,et al.  Cholesterol and mortality. 30 years of follow-up from the Framingham study. , 1987, JAMA.

[24]  P. Wilson,et al.  Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. , 1986, JAMA.

[25]  J. Neaton,et al.  Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). , 1986, JAMA.

[26]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[27]  D. Dillman,et al.  How to conduct your own survey , 1994 .